Element Paper on Avidity Sequencing™ Chemistry Published in Nature Biotechnology

Sequencing by Avidity enables high accuracy with low reagent consumption

SAN DIEGO, CA (May 25, 2023) – Element Biosciences, Inc., the developer of the Element AVITI™ System, an innovative DNA sequencing platform disrupting genomics, has published a paper on its novel Avidity Sequency chemistry in Nature Biotechnology.

The paper details Avidity Sequencing and the performance improvements it directly enables, including high quality, sustained accuracy through homopolymers, and dramatically lower reagent consumption.

Element demonstrates that Avidity sequencing achieves accuracy surpassing an average of one error per 10,000 base pairs (Q40) and enables a diversity of applications that include single-cell RNA-seq and whole-human-genome sequencing. Element also demonstrates an improved ability of this chemistry to sequence through homopolymer sequences.

For more information, please see the full paper in Nature Biotechnology.
Please see our website for a list of publicly available datasets made with Element Biosciences technology.

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company focused on developing disruptive DNA sequencing technology for research markets. Through innovating every fundamental element of a sequencing system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic research. To learn more about Element, please visit www.elementbiosciences.com.

Media Contact:

Kristi Heim
Element Biosciences